Menu Search
Equities

Lobe Sciences Ltd

6YX0:DEU

Lobe Sciences Ltd

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with partners, is engaged in drug research and development using sub-hallucinatory doses of proprietary compounds to treat Orphan diseases. Its new chemical entities, L-130 and L-131, are being developed to address unmet medical needs such as Chronic Cluster Headaches and other Orphan diseases. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd. and Altemia & Company, LLC.

  • Revenue in CAD (TTM)976.74k
  • Net income in CAD-2.85m
  • Incorporated2010
  • Employees--
  • Location
    Lobe Sciences LtdSuite 1400-1199 West Hastings StreetVANCOUVER V6E 3T2CanadaCAN
  • Phone+1 (604) 834-9499
  • Fax+1 (604) 628-1249
  • Websitehttps://www.lobesciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.